Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mebrofenin→

Mebrofenin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
78266-06-5
Molecular formula
C15H19BrN2O5
Molecular weight
387.23 g/mol
Drug class
Diagnostic radiopharmaceuticalhepatobiliary iminodiacetic-acid (IDA) imaging agent
Mechanism of action
When labelled with technetium-99m, mebrofenin is rapidly cleared from the circulation by hepatic uptake and excreted into bile. Its gamma emissions allow visualisation of hepatobiliary transit by scintigraphy or SPECT; it has no pharmacological effect at diagnostic doses.
Indications / reported uses
  • Hepatobiliary scintigraphy to assess liver uptake, biliary excretion and gallbladder/biliary tract function, according to the radiopharmaceutical product protocol.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/technetium-tc-99m-mebrofenin · https://eanm.org/wp-content/uploads/2024/06/EANM_2023_TechGuide.pdf

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mebrofenin Environmental Risk Assessment (ERA) (the Mebrofenin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.